echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The Lead Gene completed 60 million yuan of A round of financing to develop gene therapy with original delivery technology

    The Lead Gene completed 60 million yuan of A round of financing to develop gene therapy with original delivery technology

    • Last Update: 2021-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com





    Recently, news came from the industry that Shanghai Bendao Gene Technology Co.


    , Ltd.
    (hereinafter referred to as Bendao Gene), a gene therapy development company with original delivery technology, completed a round A financing of 60 million yuan, led by Huakong Fund, Enran Venture Capital, Longmen Capital, ETP Fund, Inno Angel Fund and many other institutions followed in the investment.
    This round of financing funds will be used for preclinical and clinical development of multiple products, laboratory and team building, etc.


    According to the information on the official website of this guide gene, the company was established in 2018, focusing on in vivo gene editing and in vitro transgene therapy development.


    As we all know, gene therapy has become the third revolutionary therapy after chemical drugs and antibody drugs with its unique advantage of "one-shot cure", and has made a series of significant progress in recent years.


    The development of the technology platform of this guide gene is precisely to address this challenge.


    Dr.


    According to the information on the official website of the guide gene, based on its technology platform, the guide gene has established a research pipeline covering diseases such as diabetic macular degeneration, wet age-related macular degeneration (wAMD), and hematopoietic system genetic diseases.


    Source: Bendao Gene's official website

    Mr.


    He also said that in the future, he will support the development of this guide gene for a long time, jointly promote the company's original delivery technology and products, and help gene therapy achieve a leap from "1 to 100", so that there will be more drugs that are difficult to cure and no drugs in the future.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.